Evoke Pharma, Inc. (EVOK) Research
Evoke Pharma, Inc. operates as a specialized pharmaceutical entity, primarily focused on inventing and bringing to market therapeutic agents for various digestive system illnesses. The company's lead development candidate is Gimoti, a metoclopramide nasal spray, which has progressed through and completed its Phase 3 clinical trials. This medicine is being developed to mitigate symptoms associated with both acute and recurring diabetic gastroparesis, specifically in female patients. Evoke Pharma distributes its offerings to a broad base of healthcare professionals, encompassing digestive disease specialists, internists, general practitioners, and certain other medical providers. Established in 2007, the company's corporate offices are situated in Solana Beach, California.
Market snapshot
- Symbol
- EVOK
- Price
- $11.00
- Day change
- 0.00%
- Market cap
- $18.9M
- P/E ratio
- -5.38x
- 52-week range
- 1.94-11
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Analyst price target
- $18.00
Recent news
- Evoke Agrees to $326 Million Takeover Bid From Bally's Intralot
Evoke shareholders will be entitled to receive 0.537 new Intralot shares for each Evoke share. The deal is expected completed the deal by the first quarter of 2027.
- William Hill UK owner Evoke agrees $326 million takeover by Bally's Intralot
William Hill UK owner Evoke said on Friday it had agreed to be acquired by Bally's Intralot S.A. in a recommended all-share deal valuing the company at about £243 million ($326.23 million).
- William Hill UK owner Evoke confirms $304 million takeover bid from Bally's Intralot
William Hill UK and 888 owner Evoke confirmed on Monday that it is in talks with Greek lottery and gaming firm Bally's Intralot regarding a takeover proposal at 50 pence-per-share, valuing the betting group at 225.3 million pounds ($303.88 million).
Peer companies
Recent insider activity
- Nantahala Capital Management, LLC — J-Other (148153 shares) on 2025-12-17
- Nantahala Capital Management, LLC — J-Other (433962 shares) on 2025-12-17
- Nantahala Capital Management, LLC — J-Other (117019 shares) on 2025-12-17
- Nantahala Capital Management, LLC — J-Other (117019 shares) on 2025-12-17
- Nantahala Capital Management, LLC — J-Other (158531 shares) on 2025-12-17
Open Evoke Pharma, Inc. (EVOK) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.